was present despite the presence of retinal blood flow as confirmed by OCT. Allografts may be less vascularized than syngeneic whole eye transplantations. In addition, histopathology reveals some inflammation and neovascularization to the cornea and central degeneration of the retina. These findings serve as targets for future, therapies, improvements and investigation. Future studies of systemic and local immunosuppressive therapies are necessary to support the structural and functional success of whole-eye allotransplantation. 
PURPOSE:
Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression. The current study investigated a novel approach to immunosuppression therapy using ex vivo expanded regulatory T cells combined with a short-term immunomodulatory strategy in a murine hind limb transplantation model.
METHODS:
Fully MHC-mismatched orthotopic hind limb transplants were performed from Balb/C into C57BL/6 mice. Recipients in the experimental groups received a combination regimen consisting of 0.5mg CTLA4 Ig on day 0, 2, 4 and 6 post-transplant, 20mg/kg anti-Thy 1.2 mAb on POD-1, and 1mg/kg Rapamycin (POD 0-9), and in one group, 1 week expanded CD4+CD25+ Treg cells in combination with the above therapies. Allograft survival was monitored and flow cytometric analysis was performed to evaluate mixed chimerism and clonal deletion of alloreactive T cells. Treg activity was assessed in vitro using suppression assays in order to support and supplement in vivo data.
RESULTS:
Combination of T cell depletion and CTLA4-Ig plus short-course of Rapamycin increased VCA survival significantly compared to untreated controls (MST 105 days with combination therapy vs MST 9 days without; p<0.01). Mixed chimerism was detected in recipients receiving this combined treatment protocol with 5.013 ± 1.23 % of CD11b+ cells being donor-derived on POD 55. Vβ -TCR staining profiles in recipients after full treatment showed 1.570 ± 0.3700 % of νβ5+CD4+ T cells, while naïve C57BL/6 express 3.567 ± 0.3690 % of νβ5+CD4+ T cells, suggesting the actuation of central deletion of developing donor-reactive T cells. In order to further prolong allograft survival, one week expanded Tregs were then included in the combination therapy. The suppressive activity of the CD4+CD25+ Tregs was confirmed with in vitro suppression assays. The addition of ex vivo expanded regulatory T cells further increased VCA survival to greater than 200 days and induced long-term stable mixed chimerism with approximately 15% of CD11b cells being donor-derived on POD 55 after administration of expanded donor Tregs.
CONCLUSION:
The combination of T cell depletion, costimulation blockade, and a short-course of Rapamycin prevents VCA rejection and significantly prolongs graft survival without the need for myeloablative conditioning or maintenance therapy. Moreover, regulatory T cells added in the early post transplant period further optimize immune regulation by inducing sustained mixed chimerism. 
Characterization And Functional Analysis Of Skin Dendritic Cell Subpopulations In Vascularized Composite Allotransplantation
PURPOSE: Skin dendritic cells (DC) are believed to play an important role in both the initiation and regulation of skin alloimmunity. We have developed a technique for the isolation and characterization of distinct skin DC subsets and have demonstrated the dynamics and the associated immune response profiles in vascularized composite allotransplantation (VCA). Resident skin DC can migrate out of allogeneic skin into the recipient's skin and draining lymph nodes, and may exert regulatory functions after VCA. Thus, isolating migratory skin DC from limb transplants and examining their capacity to effect T cell immune responses is part of our ongoing effort. In the present study, we assessed the function of skin-resident and skin-migrated DC subsets on regulating the T-cell immune response and characterized their changes in VCA under topical FK506 immunosuppression.
METHODS: 1)
To evaluate the impact of topical immunosuppressive treatment on the skin DC in VCA, LEW rats received hindlimb transplants from BN rats and were treated with topical FK506 (0.5mg 0.1% FK506 ointment, applied once daily). Skin-resident DC from transplanted limbs were isolated at day 8 post-transplantation using our established methods and quantification of skin DC subsets were analyzed by flow cytometry.Skin DC isolated from Naïve or 7-day topical FK506 treated untransplanted LEW rats were used as comparison groups. 2) To determinethe function of skin migratory DC on the T cell immune response, DC from each group were isolated in vitro and were characterized by subset and functional specialization by mixed lymphocyte reaction(MLR) and flow cytometric analysis.
RESULTS: 1) After topical FK506 treatment, skin-resident dermal DC (DDC) declined with an elevation trend in Langerhans cells (LC). 2) Migrated LC and mature skin DC were lower, while DDC were slightly higher in FK506-treated skin explant cultures compared to naïve skin. 3) In MLR, skin-migrated DC inhibited effector T cell (Teff) proliferation and exhibited synergistic effects with regulatory T cells (Treg). 4) The addition of skin-migrated DC promoted Foxp3 expression in CD4+ T cells. In contrast, the addition of skin-resident DC decreased Foxp3 and promoted IL-17 expression.
CONCLUSIONS:
In vivo alterations of skin-resident DC subsets and ex vivo emigration and maturation of skin DC are affected by a short-term topical immunosuppression in VCA.There is differential contribution of skin-migrated and skin-resident DC to the effector T cell response in vitro. The determination of skin-migrated DC in regulating T-cell immune responses will provide a target for immunomodulation. 
